Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease stratification using in-depth plasma proteomics has not been performed to date. By measuring more than 1000 proteins in the plasma of 147 DLBCL patients using data-independent acquisition mass spectrometry and antibody array, DLBCL patients were classified into four proteomic subtypes (PS-I-IV). Patients with the PS-IV subtype and worst prognosis had increased levels of proteins involved in inflammation, including a high expression of metalloproteinase inhibitor-1 (TIMP-1) that was associated with poor survival across two validation cohorts (n = 180). Notably, the combination of TIMP-1 with the international prognostic index (IPI) identified 64.00% to 88.24% of relapsed and 65.00% to 80.49% of deceased patients in the discovery and two validation cohorts, which represents a 24.00% to 41.67% and 20.00% to 31.70% improvement compared to the IPI score alone, respectively. Taken together, we demonstrate that DLBCL heterogeneity is reflected in the plasma proteome and that TIMP-1, together with the IPI, could improve the prognostic stratification of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Molecular & cellular proteomics : MCP - 22(2023), 9 vom: 26. Sept., Seite 100625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lou, Ning [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody microarray |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 26.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mcpro.2023.100625 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360000339 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360000339 | ||
| 003 | DE-627 | ||
| 005 | 20231226082053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mcpro.2023.100625 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM360000339 | ||
| 035 | |a (NLM)37500057 | ||
| 035 | |a (PII)S1535-9476(23)00136-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lou, Ning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease stratification using in-depth plasma proteomics has not been performed to date. By measuring more than 1000 proteins in the plasma of 147 DLBCL patients using data-independent acquisition mass spectrometry and antibody array, DLBCL patients were classified into four proteomic subtypes (PS-I-IV). Patients with the PS-IV subtype and worst prognosis had increased levels of proteins involved in inflammation, including a high expression of metalloproteinase inhibitor-1 (TIMP-1) that was associated with poor survival across two validation cohorts (n = 180). Notably, the combination of TIMP-1 with the international prognostic index (IPI) identified 64.00% to 88.24% of relapsed and 65.00% to 80.49% of deceased patients in the discovery and two validation cohorts, which represents a 24.00% to 41.67% and 20.00% to 31.70% improvement compared to the IPI score alone, respectively. Taken together, we demonstrate that DLBCL heterogeneity is reflected in the plasma proteome and that TIMP-1, together with the IPI, could improve the prognostic stratification of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antibody microarray | |
| 650 | 4 | |a diffuse large B-cell lymphoma | |
| 650 | 4 | |a mass spectrometry | |
| 650 | 4 | |a prognostic biomarker | |
| 650 | 4 | |a proteomics | |
| 650 | 7 | |a Tissue Inhibitor of Metalloproteinase-1 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Wang, Guibin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanrong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Qiaoyun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Qiaofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaomei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Rongrong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shasha |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Le |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Jiarui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhishang |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yuankai |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Xiaohong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular & cellular proteomics : MCP |d 2002 |g 22(2023), 9 vom: 26. Sept., Seite 100625 |w (DE-627)NLM119677326 |x 1535-9484 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:9 |g day:26 |g month:09 |g pages:100625 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mcpro.2023.100625 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 9 |b 26 |c 09 |h 100625 | ||